Ozempic
Also called semaglutide injection, Ozempic pen.
By Dr Chad Okay4 min read
Ozempic is a brand name for semaglutide, a weekly injection licensed for type 2 diabetes. It is a GLP-1 receptor agonist, meaning it mimics a gut hormone that lowers blood sugar, slows stomach emptying, and reduces appetite. The same drug at a higher dose is sold as Wegovy for weight loss. Ozempic is not licensed for weight loss in the UK.
What Ozempic actually is
Ozempic is the brand name Novo Nordisk uses for semaglutide injections at doses of 0.25 mg, 0.5 mg, 1 mg, and 2 mg, taken once a week. The active drug, semaglutide, is the same as in Wegovy and in oral Rybelsus, but at different doses and with different licensed uses.
How it works
Semaglutide mimics GLP-1, a hormone your gut releases after meals. GLP-1 prompts the pancreas to release insulin, slows the rate at which food leaves the stomach, and signals fullness to the brain. The combined effect lowers blood sugar after meals and reduces overall food intake. The weight-loss effect is largely a downstream consequence of eating less for longer.
What it is licensed for
- Type 2 diabetes in adults whose blood sugar is not controlled on metformin or other oral medications.
- Reducing the risk of major cardiovascular events in adults with type 2 diabetes and existing heart disease.
- Not licensed for weight loss in the UK or US. The same molecule at a higher 2.4 mg weekly dose is licensed for weight loss as Wegovy.
Common side effects
- Nausea, especially in the first 4 to 8 weeks. Usually settles as the body adjusts.
- Constipation. Slowed gut transit is part of the mechanism. Pooled SUSTAIN/PIONEER trial data put the rate at around 6% on diabetes doses of semaglutide (Aroda 2023, 5.8-6.5% across subcutaneous and oral semaglutide), much lower than higher-dose Wegovy 2.4 mg (around 23% in STEP 1, Wilding 2021; 24.2% pooled across STEP 1-3, Wharton 2022).
- Reflux and burping. Food sits longer in the stomach and pressure rises.
- Loss of appetite. The intended effect, but it can mean missed meals and dehydration if not managed.
- Tiredness and brain fog in early weeks, often linked to lower calorie intake.
- Rare but serious: pancreatitis, gallstones, and severe gastroparesis. Sharp, persistent abdominal pain needs a doctor the same day, not a wait-and-see approach (see below).
If something feels wrong
This entry is reference information, not medical guidance. Your doctor and pharmacist know you and your medicine; if anything about how you feel worries you, speak to them promptly, and if you ever feel seriously unwell, treat it as an emergency. The medicine's own patient information leaflet carries the important safety information and is worth reading in full.
Ozempic vs Wegovy vs Mounjaro
Ozempic and Wegovy are the same drug, semaglutide, at different licensed doses and indications. Mounjaro is tirzepatide, a different molecule that activates both GLP-1 and GIP receptors and tends to produce slightly more weight loss in head-to-head trials. Access in the UK depends on the indication: type 2 diabetes runs through the NHS pathway, while weight management means Wegovy or Mounjaro, either under NICE criteria or by private prescription.
Common questions
Same drug, semaglutide. Different doses and different licensed uses. Ozempic goes up to 2 mg weekly for diabetes. Wegovy goes up to 2.4 mg weekly for weight loss. The pens look similar but are not interchangeable.
Sources
- 1Ozempic 0.5 mg solution for injection - Summary of Product Characteristics (SmPC)EMC (UK)
- 2Semaglutide (Ozempic, Rybelsus, Wegovy): uses, how it works and side effectsNHS
- 3Multisociety clinical practice guidance for the safe use of GLP-1 receptor agonists in the perioperative period (2024)Clinical Gastroenterology and Hepatology
- 4Marso et al 2016, Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)New England Journal of Medicine
- 5Wilding et al 2021, Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)New England Journal of Medicine (PubMed)
- 6Wharton et al 2022, Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg (pooled STEP 1-3)Diabetes, Obesity and Metabolism
- 7Wilding et al 2022, Weight regain after withdrawal of semaglutide: the STEP 1 trial extensionDiabetes, Obesity and Metabolism
- 8Drugs@FDA: Ozempic (semaglutide) NDA 209637 - approval history including the 2020 cardiovascular risk-reduction indicationUS Food and Drug Administration




